Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Cancer Lett. 2023 Apr 14;563:216185. doi: 10.1016/j.canlet.2023.216185

Figure 5: SCH-479833 inhibits in-situ PC cell proliferation and survival.

Figure 5:

All figures show representative photomicrographs of IHC staining with different markers in CD18/HPAF (A and B) and KC (C and D) tumors derived from mice treated with HPβCD (control) and SCH-479833 (CXCR2/1 antagonist). A. Ki-67 and CC3 IHC shows a decrease in cell proliferation increased apoptosis after CXCR2 antagonist treatment in CD18/HPAF tumor-bearing mice. B. The bar graph shows the difference in the number of Ki-67 and CC3 positive cells in HPβCD and SCH-479833 treatment groups in CD18/HPAF tumor-bearing animals. C. Ki-67 and CC3 IHC show decreased cell proliferation and increased apoptosis after CXCR2 antagonist treatment in KC-tumor-bearing mice. D. The bar graph shows the difference in the number of Ki-67 and CC3 positive cells in HPβCD and SCH-479833 treatment groups in KC-tumor-bearing animals. The error bars in the graphs represent the SEM. Scale bar=100 μm. F. Relative mRNA expression of Bcl2 and Bax genes as determined by qRT-PCR.